TickerStat.comwe like data

Ocular Therapeutix, Inc (OCUL)

Price$10.64Cached quote
OCULNasdaq
Loading local price history

Financial charts

Revenue

Net income

Free cash flow

Total cash / debt

CashTotal debt

Financial statements

14 annual periodsNewest to oldest
20252024202320222021202020192018201720162015201420132012
Revenue$52.0M$63.7M$58.4M$51.5M$43.5M$17.4M$4.2M$2.0M$1.9M$1.9M$1.8M$772,000—$10,000
Gross profit$45.4M$58.1M$53.2M$47.0M$39.1M$15.3M$1.9M$1.5M$1.5M$1.4M$1.4M$681,000—$3,000
Gross margin87.35%91.17%90.96%91.18%89.88%88.03%45.00%76.63%76.24%76.52%81.77%88.21%—30.00%
Research & development$197.1M$127.6M$61.1M$53.5M$50.1M$28.7M$41.1M$36.9M$30.9M$27.1M$26.6M$18.9M$10.5M$11.5M
Operating expenses$322.0M$235.5M$140.8M$130.1M$121.6M$80.3M$90.0M$61.1M$63.8M$45.2M$39.9M$27.9M$12.9M$13.7M
Operating income−$270.0M−$171.8M−$82.4M−$78.7M−$78.0M−$62.8M−$85.8M−$59.1M−$61.9M−$43.3M−$38.2M−$27.1M−$12.9M−$13.7M
Operating margin−519.75%−269.57%−140.96%−152.74%−179.30%−361.13%−2,029.86%−2,970.75%−3,220.12%−2,296.03%−2,182.69%−3,509.59%—−136,710.00%
EBITDA−$265.7M−$168.0M−$79.4M−$76.5M−$75.6M−$60.1M−$83.3M−$56.8M−$60.3M−$42.4M−$37.4M−$26.5M−$12.5M−$13.3M
EBITDA margin−511.43%−263.63%−135.86%−148.65%−173.74%−345.19%−1,970.00%−2,855.88%−3,135.62%−2,249.34%−2,139.60%−3,438.73%—−132,670.00%
Net income−$265.9M−$193.5M−$80.7M−$71.0M−$6.6M−$155.6M−$86.4M−$60.0M−$63.4M−$44.7M−$39.7M−$28.6M−$13.3M−$14.1M
Net profit margin−511.90%−303.67%−138.14%−137.95%−15.06%−894.31%−2,043.34%−3,013.97%−3,296.20%−2,369.00%−2,271.31%−3,710.88%—−140,930.00%
Basic EPSper basic share-$1.42-$1.22-$1.01-$0.92-$0.09-$2.56-$1.91-$1.57-$2.20-$1.80-$1.71-$2.69-$5.11-$5.60
Diluted EPSper diluted share-$1.42-$1.22-$1.02-$0.97-$0.98-$2.56-$1.91-$1.57-$2.20-$1.80-$1.71-$2.69-$5.11-$5.60
Review official source filings ↗

Owners

Reported shareholders

Reference date Jun 30, 2026
FMR LLC · 14.96% of listed sharesDeep Track Capital, LP · 8.97% of listed sharesBlackRock, Inc. · 8.82% of listed sharesAvoro Capital Advisors LLC · 5.71% of listed sharesSummer Road LLC · 5.56% of listed sharesVenrock Adviser, LLC · 4.71% of listed sharesVANGUARD CAPITAL MANAGEMENT LLC · 4.02% of listed sharesPRICE T ROWE ASSOCIATES INC /MD/ · 3.47% of listed sharesLogos Global Management LP · 2.41% of listed sharesSTATE STREET CORP · 2.38% of listed sharesGEODE CAPITAL MANAGEMENT, LLC · 2.29% of listed sharesPoint72 Asset Management, L.P. · 1.50% of listed sharesDugel Pravin · ≈1.50% of listed sharesDIMENSIONAL FUND ADVISORS LP · 1.27% of listed sharesDELTEC ASSET MANAGEMENT LLC · 1.13% of listed sharesBalyasny Asset Management L.P. · 1.03% of listed sharesOctagon Capital Advisors LP · 0.94% of listed sharesVANGUARD PORTFOLIO MANAGEMENT LLC · 0.90% of listed sharesNORTHERN TRUST CORP · 0.82% of listed sharesGOLDMAN SACHS GROUP INC · 0.80% of listed shares
14.96%of listed shares
FMR LLC32.84M shares · Jun 30, 2026
View holders
Top 20 reported holders of OCUL
Holder% owned
FMR LLC
14.96%32.84M shares
Deep Track Capital, LP
8.97%19.69M shares
BlackRock, Inc.
8.82%19.38M shares
Avoro Capital Advisors LLC
5.71%12.54M shares
Summer Road LLC
5.56%12.21M shares
Venrock Adviser, LLC
4.71%10.35M shares
VANGUARD CAPITAL MANAGEMENT LLC
4.02%8.83M shares
PRICE T ROWE ASSOCIATES INC /MD/
3.47%7.62M shares
Logos Global Management LP
2.41%5.3M shares
STATE STREET CORP
2.38%5.23M shares
GEODE CAPITAL MANAGEMENT, LLC
2.29%5.02M shares
Point72 Asset Management, L.P.
1.50%3.29M shares
Dugel Pravin
≈1.50%3.29M shares
DIMENSIONAL FUND ADVISORS LP
1.27%2.78M shares
DELTEC ASSET MANAGEMENT LLC
1.13%2.48M shares
Balyasny Asset Management L.P.
1.03%2.27M shares
Octagon Capital Advisors LP
0.94%2.08M shares
VANGUARD PORTFOLIO MANAGEMENT LLC
0.90%1.97M shares
NORTHERN TRUST CORP
0.82%1.8M shares
GOLDMAN SACHS GROUP INC
0.80%1.76M shares

Percentages use 219.59M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.

Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.

Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data

Insider buys & sells

Jul 1, 2024–Jun 30, 2026
Buys2$531.0K disclosed value
Sells (SEC code S)46$4.58M disclosed value
48 recent transactions
TransactionInsiderTypeSharesPriceValueOwned after
Jun 3, 2026Form 4 · 10b5-1Waheed NadiaChief Medical OfficerSellCommon Stock14.8K$8.27$122.6K300.1K
May 26, 2026Form 4 · 10b5-1Dugel PravinSee RemarksSellCommon Stock21.2K$8.20$173.5K2.60M
May 26, 2026Form 4 · 10b5-1Kaiser PeterChief Development OfficerSellCommon Stock3.0K$8.20$24.3K266.1K
May 26, 2026Form 4 · 10b5-1Heier Jeffrey S.Chief Scientific OfficerSellCommon Stock3.0K$8.20$24.7K320.4K
May 26, 2026Form 4 · 10b5-1Nayak SanjayChief Strategy OfficerSellCommon Stock1.9K$8.20$15.2K328.8K
Review ownership filings at SEC.gov ↗

Community posts

View community

It’s quiet here.

No posts about OCUL yet. Start the conversation.

Write the first post